Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Pfizer

AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.

3 Dividend Stocks to Buy and Hold for the Next Decade

Apple

Amazon

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

Eli Lilly (LLY) reports earnings before the bell Tuesday, with investors and analysts watching to see how much weight-loss drugs are continuing to drive the company's growth.

What You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday

Eli Lilly stock (NYSE: LLY) will report its Q1 results on Tuesday, April 30. The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the consensus estimates.

A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly's Q1

Colgate-Palmolive

Procter & Gamble

Winston Churchill reportedly told the House of Commons, “Democracy is the worst form of government, except for all the others that have been tried.” You can say pretty much the same thing about dividend investing.

Dividend Legends: 3 Stocks With Over 100 Years of Payouts

Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

QUALCOMM

Blue-chip growth stocks are all around us. Yet, finding the right fit for your particular portfolio is easier said than done.

Don't Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List

Broadcom

Exxon Mobil

The majority of leading global indices reached new highs in 2024, fueled by loose financial conditions and burgeoning enthusiasm for artificial intelligence (AI). In the U.S., this rally pushed the S&P 500 to fresh highs.

Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses

Amgen

Bristol-Myers

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Merck

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

Novo Nordisk

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

Demand is high for Eli Lilly's Zepbound, and the weight-loss drug market could reach $100 billion by the end of the decade. But one thing is getting in between some potential patients and this promising drug.

Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

NEWARK, N.J.--(BUSINESS WIRE)---- $LLY #T1D--A historic fair drug-pricing lawsuit has reached a milestone moment, according to attorneys at Hagens Berman and Carella Byrne Cecchi Olstein Brody & Agnello who represent a class of those living with diabetes fighting the rising price of insulin. The law firms first began the crusade against insulin-maker Eli Lilly in 2017 and have been leading the charge to make a difference for the millions of people who rely on insulin on a daily basis, and recent activity.

Hagens Berman Signals Major Turning Point in Insulin Fair Pricing Class-Action Lawsuit

Cava Group, Inc.

Constellation Energy Corp

Disney

General Electric

Netflix

There's plenty out there that could potentially drive a broad market pullback, but there are also plenty of individual stocks due for a pullback. Irrespective how the market performs from here, these types of stocks may be in for considerable declines in price.

7 High-Flying Stocks That Are Majorly Overdue for a Pullback

Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines.

Eli Lilly to acquire manufacturing facility from Nexus Pharma

Altimmune

GoodRx Holdings

Viking Therapeutics

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Vertex Pharmaceuticals

Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.

3 Relatively Safe Growth Stocks You Can Buy and Hold

Advanced Micro Devices

Alphabet

Microsoft

ServiceNow

NVIDIA

When Wall Street tags a stock as a strong buy, it is probably right. Generally speaking, such shares tend to be among the best positioned investments in the market.

Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now

Looking ahead to the pharmaceutical earnings season, UBS expressed cautious optimism when looking at several major names. Notably, Eli Lilly and Co (NYSE:LLY), with a 'buy' rating and a price target of $910, is expected to see mixed performance due to shortages of its weightloss drig Mounjaro and Zepbound, though early stocking could partially offset declines in Trulicity sales.

Big pharma: cautious optimism ahead of earnings season - analysts

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Tesla

Tesla's transformation over the past 10 years has made it one of the most valuable stocks on Wall Street. The excitement around a highly promising weight-loss drug has made Eli Lilly a hot buy in recent years.

2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years

AdaptHealth Corp

ResMed

One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatments already.

Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank

Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its weight-loss drug, Zepbound, was effective in treating those who are overweight and suffer from obstructive sleep apnea (OSA).

Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea

The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.

News for Eli Lilly Stock (LLY)